Drug
Eculizumab
Eculizumab: highest development phase Post-Market, developed by Alexion, BioCryst Pharmaceuticals, United Therapeutics. 11 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Alexion, BioCryst Pharmaceuticals, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Eculizumab NCT04320602 | Post-Market | Paroxysmal Nocturnal Hemoglobinuria |
| eculizumab NCT02003144 | Phase 3 | Neuromyelitis Optica |
| Eculizumab NCT04155424 | Phase 2/3 | Neuromyelitis Optica |
| Eculizumab NCT01192399 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria |
| Eculizumab NCT02093533 | Phase 2 | Membranoproliferative Glomerulonephritis |
| Eculizumab NCT01403389 | Phase 2 | Delayed Function of Renal Transplant |
| Eculizumab NCT01303952 | Phase 2 | Cold Agglutinin Disease |
| Eculizumab NCT00935883 | Phase 2 | Age-Related Macular Degeneration |
| Eculizumab NCT05116774 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Eculizumab NCT03468140 | Phase 1 | End Stage Liver Disease |
| Eculizumab NCT01221181 | Phase 1 | Dense Deposit Disease |
Latest
No recent events.
Follow Eculizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.